These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28413961)

  • 1. Incretins and Lipid Metabolism.
    Tsimihodimos V; Elisaf M
    Curr Med Chem; 2018; 25(18):2133-2139. PubMed ID: 28413961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into incretin-based therapies for treatment of diabetic dyslipidemia.
    Stemmer K; Finan B; DiMarchi RD; Tschöp MH; Müller TD
    Adv Drug Deliv Rev; 2020; 159():34-53. PubMed ID: 32485206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New and emerging regulators of intestinal lipoprotein secretion.
    Xiao C; Dash S; Morgantini C; Lewis GF
    Atherosclerosis; 2014 Apr; 233(2):608-615. PubMed ID: 24534456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incretin system and its role in type 2 diabetes mellitus.
    Holst JJ; Vilsbøll T; Deacon CF
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Modulation of the incretin effect in the treatment of diabetes].
    Vidal J
    Med Clin (Barc); 2014; 143 Suppl 2():8-11. PubMed ID: 25326837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin effect: GLP-1, GIP, DPP4.
    Kazafeos K
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S32-6. PubMed ID: 21864749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states.
    Farr S; Adeli K
    Curr Opin Lipidol; 2012 Feb; 23(1):56-61. PubMed ID: 22123671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men.
    Matikainen N; Björnson E; Söderlund S; Borén C; Eliasson B; Pietiläinen KH; Bogl LH; Hakkarainen A; Lundbom N; Rivellese A; Riccardi G; Després JP; Alméras N; Holst JJ; Deacon CF; Borén J; Taskinen MR
    PLoS One; 2016; 11(1):e0145890. PubMed ID: 26752550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin-based therapies, glucometabolic health and endovascular inflammation.
    Rizzo M; Nikolic D; Banach M; Patti AM; Montalto G; Rizvi AA
    Curr Pharm Des; 2014; 20(31):4953-60. PubMed ID: 24320037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism.
    Hansen MSS; Tencerova M; Frølich J; Kassem M; Frost M
    Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):25-37. PubMed ID: 28722834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of incretin hormones and glucagon in patients with liver disease.
    Junker AE
    Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretins: what is known, new and controversial in 2013?
    Burcelin R; Thorens B;
    Diabetes Metab; 2013 Apr; 39(2):89-93. PubMed ID: 23523140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin-based therapies: where will we be 50 years from now?
    Meier JJ; Nauck MA
    Diabetologia; 2015 Aug; 58(8):1745-50. PubMed ID: 25994073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states.
    Farr S; Taher J; Adeli K
    Cardiovasc Hematol Disord Drug Targets; 2014; 14(2):126-36. PubMed ID: 24801723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of incretin secretion by dietary lipid: is it dose dependent?
    Yoder SM; Yang Q; Kindel TL; Tso P
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G299-305. PubMed ID: 19520739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut Peptides Are Novel Regulators of Intestinal Lipoprotein Secretion: Experimental and Pharmacological Manipulation of Lipoprotein Metabolism.
    Xiao C; Dash S; Morgantini C; Adeli K; Lewis GF
    Diabetes; 2015 Jul; 64(7):2310-8. PubMed ID: 26106188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin-based therapies: therapeutic rationale and pharmacological promise for type 2 diabetes.
    Wick A; Newlin K
    J Am Acad Nurse Pract; 2009 Nov; 21 Suppl 1():623-30. PubMed ID: 19900193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions.
    Nauck MA; Meier JJ
    Lancet Diabetes Endocrinol; 2016 Jun; 4(6):525-36. PubMed ID: 26876794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.